α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

Bibliography

• Thomsen MS, Hansen HH, Timmerman DB, Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr Pharm Des 2010;16:323-43
   PubMed Web of Science ®Google Scholar
• Parikh V, Ji J, Decker MW, Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling. J Neurosci 2010;30:3518-30
   PubMed Web of Science ®Google Scholar
• Alkondon M, Albuquerque EX. Nicotinic acetylcholine receptor alpha7 and alpha4beta2 subtypes differentially control GABAergic input to CA1 neurons in rat hippocampus. J Neurophysiol 2001;86:3043-55
   PubMed Web of Science ®Google Scholar
• Alkondon M, Pereira EF, Eisenberg HM, Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000;20:66-75
   PubMed Web of Science ®Google Scholar
• de Leon J. Smoking and vulnerability for schizophrenia. Schizophr Bull 1996;22:405-9
   PubMed Web of Science ®Google Scholar
• Sullivan JP, Donnelly-Roberts D, Briggs CA, A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand. Neuropharmacology 1996;35:725-34
   PubMed Web of Science ®Google Scholar
• Cohen C, Bergis OE, Galli F, SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306:407-20
   PubMed Web of Science ®Google Scholar
• Eaton JB, Peng JH, Schroeder KM, Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol 2003;64:1283-94
   PubMed Web of Science ®Google Scholar
• Brody AL, Mandelkern MA, London ED, Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006;63:907-15
   PubMed Web of Science ®Google Scholar
• Wooltorton JR, Pidoplichko VI, Broide RS, Dani JA. Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas. J Neurosci 2003;23:3176-85
   PubMed Web of Science ®Google Scholar
• Tu B, Gu Z, Shen JX, Characterization of a nicotine-sensitive neuronal population in rat entorhinal cortex. J Neurosci 2009;29:10436-48
   PubMed Web of Science ®Google Scholar
• Parri RH, Dineley TK. Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res 2010;7:27-39
   PubMed Web of Science ®Google Scholar
• Gay EA, Klein RC, Yakel JL. Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. J Pharmacol Exp Ther 2006;316:835-42
   PubMed Web of Science ®Google Scholar
• Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull 2005;64:519-24
   PubMed Web of Science ®Google Scholar
• Samochocki M, Hoffle A, Fehrenbacher A, Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024-36
   PubMed Web of Science ®Google Scholar
• Parri HR, Hernandez CM, Dineley KT. Research update: alpha7. nicotinic acetylcholine receptor mechanisms in Alzheimer's disease. Biochem Pharmacol 2011;82(8):931-42
   PubMed Web of Science ®Google Scholar
• van Duijn CM, Hofman A. Relation between nicotine intake and Alzheimer's disease. BMJ 1991;302:1491-4
   PubMed Web of Science ®Google Scholar
• Ott A, Slooter AJ, Hofman A, Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. Lancet 1998;351:1840-3
   PubMed Web of Science ®Google Scholar
• Ulrich J, Johannson-Locher G, Seiler WO, Stahelin HB. Does smoking. protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol 1997;94:450-4
   Google Scholar
• Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M, The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 2009;15:195-202
   PubMed Web of Science ®Google Scholar
• Chatterjee PK, Al-Abed Y, Sherry B, Metz CN. Cholinergic agonists. regulate JAK2/STAT3 signaling to suppress endothelial cell activation. Am J Physiol Cell Physiol 2009;297:C1294-306
   PubMed Web of Science ®Google Scholar
• Gronlien JH, Hakerud M, Ween H, Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 2007;72:715-24
   PubMed Web of Science ®Google Scholar
• Biton B, Bergis OE, Galli F, SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007;32:1-16
   PubMed Web of Science ®Google Scholar
• Werner P, Kawashima E, Reid J, Organization of the mouse 5-HT3 receptor gene and functional expression of two splice variants. Brain Res Mol Brain Res 1994;26:233-41
   PubMedGoogle Scholar
• Briggs CA, Schrimpf MR, Anderson DJ, Alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analogues. Br J Pharmacol 2008;153:1054-61
   PubMed Web of Science ®Google Scholar
• Boess FG, De Vry J, Erb C, The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2- carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007;321:716-25
   PubMed Web of Science ®Google Scholar
• Mullen G, Napier J, Balestra M, (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 2000;43:4045-50
   PubMed Web of Science ®Google Scholar
• Kem WR, Mahnir VM, Prokai L, Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol 2004;65:56-67
   PubMed Web of Science ®Google Scholar
• Machu TK, Hamilton ME, Frye TF, Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine(3A) receptor. J Pharmacol Exp Ther 2001;299:1112-19
   PubMed Web of Science ®Google Scholar
• Dinklo T, Shaban H, Thuring JW, Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazoleme thanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor. J Pharmacol Exp Ther 2011;336:560-74
   PubMed Web of Science ®Google Scholar
• Broad LM, Zwart R, Pearson KH, Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 2006;318:1108-17
   PubMed Web of Science ®Google Scholar
• Mazurov A, Hauser T, Miller CH. Selective alpha7 nicotinic acetylcholine receptor ligands. Curr Med Chem 2006;13:1567-84
   PubMed Web of Science ®Google Scholar
• Timmermann DB, Gronlien JH, Kohlhaas KL, An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 2007;323:294-307
   PubMed Web of Science ®Google Scholar
• Hajos M, Hurst RS, Hoffmann WE, The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 2005;312:1213-22
   PubMed Web of Science ®Google Scholar
• Broad LM, Felthouse C, Zwart R, PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur J Pharmacol 2002;452:137-44
   PubMed Web of Science ®Google Scholar
• Lopez-Hernandez G, Plac zek AN, Thinschmidt JS, Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 2007;53:134-44
   PubMed Web of Science ®Google Scholar
• Marrero MB, Papke RL, Bhatti SS, The neuroprotective effect of 2-(3-pyridyl)-1-azabicyclo[3.2.2]nonane (TC-1698), a novel alpha7 ligand, is prevented through angiotensin II activation of a tyrosine phosphatase. J Pharmacol Exp Ther 2004;309:16-27
   PubMed Web of Science ®Google Scholar
• Hajos M, Rogers BN. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia. Curr Pharm Des 2010;16:538-54
   PubMed Web of Science ®Google Scholar
• Olincy A, Harris JG, Johnson LL, Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006;63:630-8
   PubMed Web of Science ®Google Scholar
• Freedman R, Olincy A, Buchanan RW, Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008;165:1040-7
   PubMed Web of Science ®Google Scholar
• Shytle RD, Silver AA, Sheehan KH, Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress Anxiety 2002;16:89-92
   PubMed Web of Science ®Google Scholar
• Tregellas JR, Tanabe J, Rojas DC, Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 2011;69:7-11
   PubMed Web of Science ®Google Scholar
• Coyle JT, Geerts H, Sorra K, Amatniek J. Beyond in vitro data: a review of in vivo evidence regarding the allosteric potentiating effect of galantamine on nicotinic acetylcholine receptors in Alzheimer's neuropathology. J Alzheimers Dis 2007;11:491-507
   PubMed Web of Science ®Google Scholar
• Mega MS, Dinov ID, Porter V, Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005;62:721-8
   PubMed Web of Science ®Google Scholar
• Freedman R, Leonard S, Gault JM, Linkage disequilibrium for schizophrenia at the chromosome 15q13-14 locus of the alpha7-nicotinic acetylcholine receptor subunit gene (CHRNA7). Am J Med Genet 2001;105:20-2
   PubMed Web of Science ®Google Scholar
• Geerts H. Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 2009;23:915-26
   PubMed Web of Science ®Google Scholar
• Buccafusco JJ. Estimation of working memory in macaques for studying drugs for the treatment of cognitive disorders. J Alzheimers Dis 2008;15:709-20
   PubMed Web of Science ®Google Scholar
• Toyohara J, Sakata M, Wu J, Preclinical and the first clinical studies on [11C]CHIBA-1001 for mapping alpha7 nicotinic receptors by positron emission tomography. Ann Nucl Med 2009;23:301-9
   PubMed Web of Science ®Google Scholar
• Toyohara J, Ishiwata K, Sakata M, In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys. PLoS One 2010;5:e8961
   PubMedGoogle Scholar
• Ettrup A, Mikkelsen JD, Lehel S, 11C-NS14492 as a novel PET radioligand for imaging cerebral {alpha}7 nicotinic acetylcholine receptors: in vivo evaluation and drug occupancy measurements. J Nucl Med 2011;52:1449-56
   PubMed Web of Science ®Google Scholar
• Vijayraghavan S, Wang M, Birnbaum SG, Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007;10:376-84
   PubMed Web of Science ®Google Scholar